Beijing Strong BiotechnologiesInc Bilan de santé

Santé financière contrôle des critères 5/6

Beijing Strong BiotechnologiesInc possède un total de capitaux propres de CN¥4.0B et une dette totale de CN¥1.2B, ce qui porte son ratio d'endettement à 29.4%. Son actif total et son passif total sont CN¥5.5B et de CN¥1.5B. L'EBIT de Beijing Strong BiotechnologiesInc est CN¥639.4M ce qui fait que son ratio de couverture des intérêts 28.3. Elle dispose de liquidités et de placements à court terme de CN¥994.6M.

Informations clés

29.4%

Ratio d'endettement

CN¥1.17b

Dette

Ratio de couverture des intérêts	28.3x
Argent liquide	CN¥994.56m
Fonds propres	CN¥3.96b
Total du passif	CN¥1.49b
Total des actifs	CN¥5.46b

Mises à jour récentes de la santé financière

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Jul 25

Recent updates

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Jul 25

Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

Jul 03

An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

Jun 14

Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Mar 21

Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Mar 03

Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Feb 27

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 300406 ( CN¥2.6B ) dépassent ses passifs à court terme ( CN¥287.6M ).

Passif à long terme: Les actifs à court terme de 300406 ( CN¥2.6B ) dépassent ses passifs à long terme ( CN¥1.2B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 300406 ( 4.3% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de 300406 est passé de 0% à 29.4% au cours des 5 dernières années.

Couverture de la dette: La dette de 300406 est bien couverte par le flux de trésorerie opérationnel ( 53.3% ).

Couverture des intérêts: Les paiements d'intérêts de 300406 sur sa dette sont bien couverts par l'EBIT ( 28.3 x couverture).

Beijing Strong BiotechnologiesInc Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 3Q 2023)

Investor sentiment deteriorates as stock falls 19%

Beijing Strong Biotechnologies,Inc. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2023)

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

Beijing Strong Biotechnologies,Inc. to Report First Half, 2024 Results on Aug 23, 2024

An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 1Q 2023)

Upcoming dividend of CN¥0.20 per share

Beijing Strong Biotechnologies,Inc. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 07 May 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Beijing Strong Biotechnologies,Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022)

Beijing Strong Biotechnologies,Inc. to Report Q3, 2023 Results on Oct 25, 2023

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.11 in 2Q 2022)

New minor risk - Dividend sustainability

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 80 million worth of its shares.

Beijing Strong Biotechnologies, Inc. to Report First Half, 2023 Results on Aug 10, 2023

Beijing Strong Biotechnologies, Inc. Announces Dividend on Share A for 2022, Payable on May 22, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2021)

Beijing Strong Biotechnologies, Inc. (SZSE:300406) signed an Equity Transfer Agreement to acquire an additional 4.45% stake in Fuzhou Maixin Biotech. Co., Ltd. from Xinyu Yuanlang Management Consulting Partnership (Limited Partnership) for approximately CNY 130 million.

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 2Q 2021)

Beijing Strong Biotechnologies, Inc. Announces Final Dividend on A Shares for the Year 2021, Payable on 27 May 2022

Beijing Strong Biotechnologies, Inc. Approves Cash Dividend for 2021

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend Proposal for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Beijing Strong Biotechnologies, Inc. (SZSE:300406) entered into an agreement to acquire 75% stake in Wuhan Healcare Pharmaceuticals Technology Development Co., Ltd. from Xia Zhihui and Wang Ying for CNY 4 million.

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.039 in 2Q 2020)

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend for 2020, Payable on 27 May 2021

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

New 90-day low: CN¥20.29

Beijing Strong Biotechnologies, Inc. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥23.45

Third quarter earnings released

New 90-day low - CN¥19.38

First half earnings released

New 90-day high - CN¥24.20

Beijing Strong Biotechnologies, Inc. to Report First Half, 2020 Results on Aug 28, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines